Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...

FDA approval of Regeneron Pharmaceuticals’ new drug, Lynozyfic, comes with dosing flexibility that sets it apart from others in its class. By Frank Vinluan on July 02, 2025 9:53 pm.

The Food and Drug Administration (FDA) announced the first-ever approval of an Ebola drug, which is made of three monoclonal antibodies. The drug, Inmazeb, was developed by Regeneron ...

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

The latest approval expands the initial FDA approval (granted in June 2019) in CRSwNP for patients aged 18 years and older. Regeneron’s shares have rallied 31.3% year to date compared to the ...

Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA).

The U.S. Food and Drug Administration has given the green light for emergency use of Regeneron’s COVID-19 antibody drug — the same treatment given to President Trump. The treatment is a… ...

The drugmaker Regeneron said on Wednesday evening that it had submitted an application to the Food and Drug Administration for emergency approval of the experimental antibody cocktail that ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...